Global Atrial Fibrillation Market 2015-2019

About Atrial Fibrillation
According to the NHLBI of the NIH in the US, atrial fibrillation is one of the commonest type of arrhythmia. Atrial fibrillation is similar to another type of arrhythmia of the heart, superventricular tachycardia. The chief difference between these two types of arrhythmia is the consistency of the beats. In superventricular tachycardia, the heart beats are regular and at a very fast pace. Patients with atrial fibrillation experience fast and irregular heartbeats. In patients with atrial fibrillation, electrical signals travel rapidly in an uncontrolled way, which causes convulsion, palpitation or contraction in the atria of the heart. Blood is accumulated inside the atrial chambers, instead of flowing to the ventricular chambers. In this case, blood is not pumped into the ventricles fully. Also, the quantity of blood pumped out of the ventricles to the body is irregular and centered on the arbitrary atrial strokes. This can lead to the formation of blood clot in the atria. Stroke occurs in case the clot moves to the brain, which can cause death of an individual. In atrial fibrillation, the ventricles might beat for 100 to 175 times per minute, which is a stark contrast to the normal heart rate of 60 to 100 beats per minute. Atrial fibrillation is more common in older people and is detected using an ECG reading to find out the abnormalities of the electric signal. Some of the symptoms of atrial fibrillation are rapid and irregular heartbeat, palpitations, dizziness, sweating, chest pain, breathlessness, fatigue, and sometimes loss of consciousness.

TechNavio's analysts forecast the Global Atrial Fibrillation market to grow at a CAGR of 11.05 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Atrial Fibrillation market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs such as anti-arrythmics and anticoagulants used in the treatment of atrial fibrillation.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Atrial Fibrillation market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global Atrial Fibrillation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Atrial Fibrillation market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• Boehringer Ingelheim
• Janssen Pharmaceuticals
• Sanofi

Other Prominent Vendors

• ARCA Biopharma
• Armetheon
• Baxter
• Bristol-Myers Squibb
• ChanRx
• Daiichi Sankyo
• Gilead Sciences
• HUYA Biosciences
• Menarini
• Pfizer
• Pierre Fabre
• Servier
• Xention

Market Driver
• Growing Patient Base
• For a full, detailed list, view our report

Market Challenge
• High Cost of Therapy
• For a full, detailed list, view our report

Market Trend
• Shifting Focus on Emerging Markets
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?